
Benefits of tiotropium/olodaterol in patients with COPD receiving only LAMA at baseline: pooled analysis of TONADO®/OTEMTO®



Conclusion: these results support treatment escalation to dual bronchodilation in patients receiving LAMA monotherapy, without compromising patient safety

COPD, chronic obstructive pulmonary disease; FEV, forced expiratory volume in 1 second; LAMA, long-acting muscarinic antagonist; SGRQ, St. George's Respiratory Questionnaire; T/O, tiotropium/olodaterol; TDI, Transition Dyspnoea Index; tio, tiotropium

This graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. The authors, CC-BY-NC 2020.

PEER-REVIEWED INFOGRAPHIC



